Establishment Labs Holdings Inc

Establishment Labs Holdings Inc

  • Price (USD)78.00
  • Today's Change1.76 / 2.31%
  • Shares traded10.79k
  • 1 Year change+364.01%
  • Beta--
Data delayed at least 15 minutes, as of Jul 26 2021 15:03 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Establishment Labs Holdings Inc. is a medical technology and aesthetics company that is focused on patient safety and aesthetic outcomes and also in the breast aesthetics and reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. Its line of silicone gel-filled breast implants, branded as MotivaImplants, is the centerpiece of its MotivaImagine medical technology platform. The Company’s MotivaImplants are sold in over 60 countries.

  • Revenue in USD (TTM)90.53m
  • Net income in USD-27.31m
  • Incorporated2013
  • Employees521.00
  • Location
    Establishment Labs Holdings IncBuilding B15 and 25, Coyol Free ZoneALAJUELA VG1110Costa RicaCRI
  • Phone+506 24342400
  • Websitehttps://establishmentlabs.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
MiMedx Group Inc246.47m-88.36m1.32bn735.00------5.36-0.8141-0.81412.270.75241.413.747.32335,326.50-30.22-6.69-45.83-10.4584.2087.36-21.44-3.572.501.930.3636---17.055.80-225.75---7.37--
Nano-X Imaging Ltd0.00-49.11m1.33bn40.00--5.88-----1.12-
Eargo Inc-100.00bn-100.00bn1.33bn238.00--7.09----------4.85------------------------9.23--0.0744--110.90--32.11------
Alphatec Holdings Inc158.87m-81.18m1.38bn296.00--5.70--8.66-1.19-,712.80-29.08-28.67-36.08-43.1271.3467.78-51.10-34.193.16-9.970.1429--27.711.51-38.82--13.56--
Treace Medical Concepts Inc57.37m-4.31m1.43bn133.00------24.89-0.1554-0.15542.07--------431,315.80--------78.26---6.39----0.189----45.54--12.17------
Pulmonx Corp33.36m-37.11m1.46bn170.00--6.64--43.68-1.71-1.711.166.05------196,229.40--------66.44---111.25--16.22-16.960.0741--0.4234---55.68------
Cardiovascular Systems Inc230.53m-23.30m1.58bn779.00--5.83--6.84-0.6425-0.64256.096.730.81321.766.69295,933.30-8.22-8.25-9.99-10.1978.0380.57-10.11-7.714.99-13.960.071---4.635.44-10,580.78---28.11--
Inogen Inc306.93m-4.97m1.61bn938.00--4.51134.045.23-0.2265-0.226513.8815.920.65615.237.79327,217.50-1.067.15-1.218.1145.5147.76-1.627.845.11--0.000.00-14.7714.17-127.82--50.85--
Silk Road Medical Inc78.35m-48.12m1.65bn281.00--16.29--21.06-1.43-1.432.322.940.52871.797.92278,818.50-32.47---36.20--72.46---61.42--9.37-14.450.3244--18.74--9.63------
Avanos Medical Inc715.10m-38.50m1.67bn5.38k--1.33477.292.34-0.8073-0.807314.9226.060.41912.225.40132,918.20-2.26-2.42-2.51-2.8450.6955.53-5.38-7.281.834.160.1226--2.477.03-13.94---22.10--
Lantheus Holdings Inc341.22m-7.80m1.73bn595.00--3.2881.425.08-0.1761-0.17615.587.830.5476.216.57573,470.60-1.256.05-1.396.9644.3747.97-2.297.432.140.90520.2560.00-2.282.95-142.55---1.05--
Establishment Labs Holdings Inc90.53m-27.31m1.81bn521.00--24.89--19.95-1.16-1.163.833.060.56451.403.99173,763.90-17.03---19.97--63.0959.08-30.17-53.264.27-2.970.41---5.4654.580.076------
BioLife Solutions Inc52.77m-20.76m1.89bn193.00--7.52--35.74-0.8372-0.83721.746.210.3152.105.59273,430.10-12.39-12.25-14.16-13.2755.2362.13-39.34-30.196.40--0.0128--75.6949.45260.95--40.67--
Butterfly Network Inc12.44m-132.89m2.03bn260.00--4.66--163.27-2.64-2.640.19382.280.0384----47,857.69-41.03---44.66--51.56---1,068.02--10.87-0.7510.00--------------
Outset Medical Inc65.66m-112.74m2.04bn313.00--6.20--31.05-2.63-2.631.517.150.22995.306.89209,779.50-45.82---51.17---13.99---199.31--8.53-59.480.0883--231.18--7.18------
Glaukos Corp237.59m-82.76m2.31bn653.00--3.89--9.72-1.85-1.855.2812.820.26363.537.25363,845.30-9.18-6.01-11.69-6.6068.0978.99-34.83-12.371.37-5.370.3657---5.0725.69-880.26---15.27--
Data as of Jul 26 2021. Currency figures normalised to Establishment Labs Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

53.31%Per cent of shares held by top holders
HolderShares% Held
JW Asset Management LLCas of 31 Mar 20213.12m13.16%
RTW Investments LPas of 31 Mar 20212.32m9.79%
Nantahala Capital Management LLCas of 31 Mar 20212.06m8.70%
Brown Advisory LLCas of 31 Mar 20211.55m6.53%
Pura Vida Investments LLCas of 31 Mar 20211.10m4.65%
Perceptive Advisors LLCas of 31 Mar 2021987.29k4.17%
UBS Securities LLCas of 31 Mar 2021399.84k1.69%
Cowen & Co. LLCas of 31 Mar 2021386.05k1.63%
Artisan Partners LPas of 31 Mar 2021375.24k1.58%
Apo Asset Management GmbHas of 31 May 2021335.60k1.42%
More ▼
Data from 31 Mar 2021 - 30 Jun 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.